- Home
- MDCX vs VANI Comparison
MDCX vs VANI Comparison
Compare MDCX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | VANI |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 95.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MDCX | VANI |
|---|---|---|
| Price | $0.50 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.50 | $4.00 |
| AVG Volume (30 Days) | ★ 8.1M | 191.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $0.91 |
| 52 Week High | $8.90 | $1.92 |
Technical Indicators
Market Signals| Indicator | MDCX | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 49.73 |
| Support Level | $0.37 | $1.17 |
| Resistance Level | $1.43 | $1.27 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 10.14 | 74.74 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.